Our internal pipeline is focused on creating next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system for a variety of cancer indications, including our lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting ADC. We have established collaborations with multiple pharmaceutical companies including NovoCodex Biopharmaceuticals, Sino Biopharmaceuticals, and BeiGene in additional indications and development projects.
Our team of dedicated professionals is bound by a culture and vision that embraces innovation, practicality, and accountability. Through these shared values, we relentlessly pursue our mission of bringing engineered precision biologics to patients in need of new targeted and stable treatment options. Visit our Careers page for information about joining our team.